Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-Like Peptide 1 Agonists

Diabetes Care - United States
doi 10.2337/dc11-s228
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Diabetes Association

Related search

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Effects of Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 and Glucagon-Like Peptide-1 Receptor Agonists on Bone Cell Metabolism

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

Effects of Glucagon-Like Peptide 1 on Appetite and Body Weight: Focus on the CNS

Journal of Endocrinology
EndocrinologyMetabolismDiabetes
2013English

Synthesis and Biological Evaluation of Glucagon-Like Peptide-1 Receptor Agonists

Archives of Pharmacal Research
Organic ChemistryDrug DiscoveryMolecular Medicine
2013English

Cardiovascular and Hemodynamic Effects of Glucagon-Like Peptide-1

Reviews in Endocrine and Metabolic Disorders
EndocrinologyMetabolismDiabetes
2014English

Glucagon-Like Peptide 1 Receptor Agonists: A New Approach to Type 2 Diabetes Management

South African Family Practice
2013English

Pdb12 - Cardiovascular Safety of Empagliflozin Versus Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists: Systematic Literature Review and Indirect Comparisons

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2014English

Glucagon-Like Peptide-1 and Satiety

Nature
Multidisciplinary
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy